Immunofluorescence analysis in clinical GBM samples demonstrated that there were malignant cells with co-staining of TNFRSF14 and GFAP, indicating cancer intrinsic TNFRSF14 expression in GBM (Fig. 1E). The gene discussed is GFAP; the disease is glioblastoma.